Navigation Links
Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
Date:5/18/2011

the company's website at www.onyx-pharm.com.

Forward Looking Statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer Web site at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2010, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
2. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
3. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
4. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
5. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
6. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
7. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
8. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
9. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
10. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
11. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 Today, DripDrop, the ... the formation of the DripDrop Foundation, with its ... dehydration worldwide. Utilizing scientific advancements in Oral Rehydration ... to reduce dehydration and healthcare costs through strategic ... "DripDrop has been used in ...
(Date:9/23/2014)... , Sept. 23, 2014   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... new additions to its Scientific Advisory Board.  The new ... Anthony Davies , PhD. Dr. Acker is ...
(Date:9/22/2014)... BARCELONA , España, September 23, 2014 ... nube permite que los patrocinadores de ensayos clínicos satisfagan ... a la accesibilidad y exhaustividad de los expedientes permanentes ... La mayor encuesta sobre TMF en el ... un aumento en el número de patrocinadores de ensayos ...
Breaking Medicine Technology:DripDrop Forms Foundation To Scale Relief Efforts 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 2El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 3El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 4El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 5
... Adeona Pharmaceuticals, Inc. (AMEX: ... for serious central nervous system diseases, announced today ... the randomized, double-blind, placebo-controlled, multi-center clinical trial of ... multiple sclerosis (MS) in women, per the original ...
... MARLBOROUGH, Mass., Sept. 19, 2011 Advanced Cell Technology, ... of regenerative medicine, announced today that it has been ... the Company,s proprietary method for generating and expanding hemangioblast ... an exclusive license to commercialize the patented technology in ...
Cached Medicine Technology:Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 2Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 3Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 4Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 5ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders 2ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders 3ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders 4
(Date:9/23/2014)... California (PRWEB) September 23, 2014 ... transcription is the process of translating the entire ... course, therapeutic procedures, and prognosis, into a readable ... agents, patients, and healthcare providers. With attending physicians ... each patient’s condition, outsourcing of such documentation to ...
(Date:9/23/2014)... go to Mars, will astronauts be able to grow ... they be able to produce food in NASA,s Orion ... growing food on Earth under extreme conditions? These are ... growth in microgravity on the International Space Station (ISS). ... fundamental genetic mechanisms plants use to adapt to a ...
(Date:9/23/2014)... NJ (PRWEB) September 23, 2014 Visiting ... provider of home health care, hospice and palliative care, ... to ring the Opening Bell last week at the ... a New Jersey philanthropist and social entrepreneur to care ... VNA Health Group has always worked to meet the ...
(Date:9/23/2014)... Becker's Hospital Review has published the 2014 edition ... Systems With Great Orthopedic Programs." , The hospitals ... orthopedic surgery departments, programs or dedicated centers that ... orthopedic departments include physicians who provide outstanding care ... athletes. , This is the fifth year Becker's ...
(Date:9/23/2014)... better screening strategies can lower the rate of false-positive ... on women. The many misperceptions about breast cancer screening ... and the need for new approaches and better education ... supplement to Journal of Women,s Health , a ... supplement is available free on the Journal of ...
Breaking Medicine News(10 mins):Health News:Expanding Healthcare Sector Drives Demand for Medical Transcription Services, According to New Report by Global Industry Analysts, Inc. 2Health News:Expanding Healthcare Sector Drives Demand for Medical Transcription Services, According to New Report by Global Industry Analysts, Inc. 3Health News:Getting to the root of the problem in space 2Health News:Getting to the root of the problem in space 3Health News:Getting to the root of the problem in space 4Health News:NJ's Largest Nonprofit Home Health Care Agency Joins Deutsche Bank to Ring New York Stock Exchange Opening Bell 2Health News:125 Hospitals With Great Orthopedic Programs 2Health News:125 Hospitals With Great Orthopedic Programs 3Health News:125 Hospitals With Great Orthopedic Programs 4Health News:125 Hospitals With Great Orthopedic Programs 5Health News:Opportunities to reduce patient burden associated with breast cancer screening 2
... in Attack and Stalking at Homes, OAKLAND, Calif., ... on a labor conference in Michigan Saturday night by ... Nurses Organizing Committee Monday called on SEIU,President Andrew Stern ... nurses, and working people for threats and harassment.", ...
... to,the State of Iowa,s new smoke-free law, the American ... Tobacco-Free" conference on April,29th in Coralville, Iowa to assist ... will offer information on the new law,and feature speakers ... businesses that have questions about the law and the ...
... identified in the blood of chronic sinusitis sufferers that ... disease, researchers say. , They used a sophisticated research ... proteins and found among 96 chronic sinusitis patients a ... can diagnose this disease with a totally objective test ...
... month, two,men from Massachusetts will begin The Elias Tembenis ... autism awareness and funds to,assist children with the diagnosis., ... walk approximately,3000 miles in honor of Elias Tembenis, a ... a seizure. Tembenis family friends,Williams and Genese hope to ...
... 14 A board-certified,radiologist, Fred Steinberg, M.D., his ... Fla., have reached a settlement with the United,States ... Justice Department,announced today. Under the terms of the ... resolves allegations that portions of CT scans were ...
... Region 5 has reached an agreement with American ... coal preparation,plant at 43521 Mayhugh Hill Road, Township ... includes a $40,000 penalty, resolves EPA,allegations that AEC ... at the plant that processes coal from a ...
Cached Medicine News:Health News:RNs Call on Service Employees Union (SEIU) President Stern to Renounce Violence Following Brutal Attack on Labor Event 2Health News:RNs Call on Service Employees Union (SEIU) President Stern to Renounce Violence Following Brutal Attack on Labor Event 3Health News:Potential blood test for chronic sinusitis identified 2Health News:Two Men to Walk Across America for Autism Aid, Awareness, and Loving Memory of Young Boy 2Health News:Florida Radiologist to Pay U.S. $7 Million to Resolve Fraud Claims 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... face is the most widely used contrast sensitivity ... four (4) rows of sine-wave gratings. At the ... these gratings test the spatial frequencies of 3, ... a full contrast sensitivity curve, which is very ...
Medicine Products: